01/07/2026
REGULATORY UPDATE: U.S. Food and Drug Administration on Data Gaps, Recall Guidance, Warning Letters/Recalls and New Hair Growth Pill Reaching Phase III Trials
The U.S. Food and Drug Administration (FDA) has taken several steps in recent months to enhance and regulatory oversight for cosmetics and pharmaceuticals, and to support treatments.
Specific actions include: reviewing PFAS in cosmetics (and finding insufficient data), proposing MoCRA-conferred recall guidance, enforcing compliance through warning letters and recalls, and advancing trials for a new hair loss treatment.
For more details, see: https://brnw.ch/21wYSAK